NCT00290706View on ClinicalTrials.gov

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 7, 2006

Primary Completion Date

February 11, 2011

Study Completion Date

September 5, 2012

Conditions
Lymphoma
Interventions
DRUG

bortezomib

Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.

DRUG

gemcitabine hydrochloride

Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.

Trial Locations (3)

60611

Northwestern University, Chicago

Veterans Affairs Medical Center - Lakeside Chicago, Chicago

60637

University of Chicago Cancer Research Center, Chicago

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Northwestern University

OTHER

NCT00290706 - A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter